Accelerating Medicines Partnership® SCHIZOPHRENIA
Participating in the Study
Participating in the Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) research study will allow scientists to understand better what happens to young people at clinical high risk for psychosis. By knowing more, scientists can improve mental health interventions and the support provided to young people.

Participating in the Study


If you or a family member has been invited to participate in this study, you may have lots of questions. This section will describe the purpose of the study, what’s involved, and who is eligible to take part. There is also a list of frequently asked questions that may answer some of your questions.

Participants in this research study will help scientists understand better long-term outcomes for young people who are at clinical high risk for psychosis and who may be at increased risk for developing schizophrenia or a related disorder later. Scientists will use the results of this study to improve mental health interventions and support for young people who are at clinical high risk for psychosis.


Last Reviewed on May 2, 2022